FDA Approves Labeling Supplement for Puma Biotechnology"s NERLYNX (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
LOS ANGELES--(BUSINESS WIRE)--Oct 2, 2019--
LOS ANGELES--(BUSINESS WIRE)--Oct 2, 2019--